Case report: Eculizumab plus obinutuzumab induction in a deceased donor kidney transplant recipient with DEAP-HUS

The wide-spread use of the anti-complement component 5 monoclonal antibody (moAb) eculizumab has greatly reduced the incidence of relapsing atypical hemolytic uremic syndrome (aHUS) after kidney transplantation (KT). However, the optimal management of aHUS transplant candidates with anti-Complement...

Descripción completa

Detalles Bibliográficos
Autores principales: Favi, Evaldo, Molinari, Paolo, Alfieri, Carlo, Castellano, Giuseppe, Ferraresso, Mariano, Cresseri, Donata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795842/
https://www.ncbi.nlm.nih.gov/pubmed/36591301
http://dx.doi.org/10.3389/fimmu.2022.1073808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795842/
https://www.ncbi.nlm.nih.gov/pubmed/36591301
http://dx.doi.org/10.3389/fimmu.2022.1073808

Ejemplares similares